Home » Stocks » PLX

Protalix BioTherapeutics, Inc. (PLX)

Stock Price: $3.48 USD 0.00 (0.00%)
Updated December 4, 4:00 PM EST - Market closed

PLX Stock Price Chart

Key Info

Market Cap 116.01M
Revenue (ttm) 61.16M
Net Income (ttm) -6.63M
Shares Out 32.86M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE 116.28
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $3.48
Previous Close $3.48
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.48
Day's Range 3.44 - 3.52
Day's Volume 56,558
52-Week Range 2.10 - 4.61

PLX Stock News

PRNewsWire - 1 week ago

CARMIEL, Israel, Nov. 27, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

PRNewsWire - 4 weeks ago

CARMIEL, Israel, Nov. 5, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercializ...

Seeking Alpha - 1 month ago

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 1 month ago

CARMIEL, Israel, Oct. 29, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

PRNewsWire - 1 month ago

CARMIEL, Israel, Oct. 29, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

PRNewsWire - 1 month ago

CARMIEL, Israel, Oct. 26, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

PRNewsWire - 2 months ago

BOSTON and CARMIEL, Israel, Oct. 2, 2020 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi ...

Seeking Alpha - 2 months ago

Protalix Could Claim Substantial Global Market Share In Fabry Disease

PRNewsWire - 2 months ago

CARMIEL, Israel, Sept. 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

Seeking Alpha - 3 months ago

Protalix shares have gone nowhere since June.

PRNewsWire - 3 months ago

CARMIEL, Israel,, Aug. 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

PRNewsWire - 3 months ago

CARMIEL, Israel, Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

Seeking Alpha - 3 months ago

Protalix BioTherapeutics, Inc.'s (PLX) CEO Dror Bashan on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

CARMIEL, Israel, Aug. 6, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

PRNewsWire - 4 months ago

CARMIEL, Israel, Aug. 3, 2020 /PRNewswire/Protalix BioTherapeutics, Inc.

PRNewsWire - 4 months ago

CARMIEL, Israel, July 23, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

Seeking Alpha - 5 months ago

Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant

Seeking Alpha - 6 months ago

Protalix Should Go Higher If FDA Approves Fabry Disease Therapy

Seeking Alpha - 6 months ago

Protalix Bio Therapeutics (PLX) CEO, Dror Bashan on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

Seeking Alpha - 8 months ago

Protalix BioTherapeutics' (PLX) CEO Dror Bashan on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

Seeking Alpha - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Protalix (PLX) delivered earnings and revenue surprises of 50.00% and 22.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

GlobeNewsWire - 1 year ago

CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization...

GlobeNewsWire - 1 year ago

CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercializati...

Seeking Alpha - 1 year ago

Protalix Biotherapeutics, Inc. (PLX) CEO Dror Bashan on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 4.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.

Seeking Alpha - 1 year ago

Protalix Biotherapeutics, Inc. (PLX) CEO Moshe Manor on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 2.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Protalix stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q4 2018 Results - Earnings Call Transcript

CNBC Television - 2 years ago

Chip stocks on pace for second straight down week

The "Fast Money Halftime Report" traders debate whether to buy the dip in chip stocks, including Nvidia, Intel, Micron and Applied Materials.

Other stocks mentioned: AMAT, LRCX, MU, NVDA, QCOM, QRVO, SMH, SOXX, XLK

About PLX

Protalix BioTherapeutics, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry dise... [Read more...]

Industry
Biotechnology
IPO Date
May 15, 1998
CEO
Dror Bashan
Employees
196
Stock Exchange
NYSE American
Ticker Symbol
PLX
Full Company Profile

Financial Performance

In 2019, PLX's revenue was $54.69 million, an increase of 59.73% compared to the previous year's $34.24 million. Losses were -$18.28 million, -30.92% less than in 2018.

Financial Statements